{"id":"high-dose-dual-therapy","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL5984914","moleculeType":null,"molecularWeight":"296.37"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Without specification of the exact agents, high dose dual therapy generally refers to a combination treatment strategy where two drugs are administered at higher-than-standard doses to enhance efficacy. This approach is often used in oncology, infectious disease, or cardiovascular conditions where combination therapy provides superior outcomes compared to monotherapy. The specific mechanism depends on the individual drugs and their molecular targets.","oneSentence":"High dose dual therapy typically combines two active pharmaceutical agents at elevated doses to achieve synergistic therapeutic effects.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:47:39.852Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07287670","phase":"PHASE2","title":"EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)","status":"NOT_YET_RECRUITING","sponsor":"Mediar Therapeutics","startDate":"2026-02","conditions":"Diffuse Cutaneous Systemic Sclerosis","enrollment":85},{"nctId":"NCT07496567","phase":"PHASE2, PHASE3","title":"A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)","status":"NOT_YET_RECRUITING","sponsor":"EyeBiotech Ltd.","startDate":"2026-04-30","conditions":"Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization","enrollment":960},{"nctId":"NCT07296094","phase":"PHASE2","title":"Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder","status":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-05-01","conditions":"Alcohol Use Disorder","enrollment":36},{"nctId":"NCT04864314","phase":"NA","title":"Assessment of TetraSOD® Efficacy to Improve Semen Parameters in Men With Idiopathic Infertility","status":"COMPLETED","sponsor":"Fitoplancton Marino, S.L.","startDate":"2021-05-12","conditions":"Infertility, Male","enrollment":80},{"nctId":"NCT07489885","phase":"PHASE2","title":"A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis","status":"NOT_YET_RECRUITING","sponsor":"InventisBio Co., Ltd","startDate":"2026-05","conditions":"Psoriasis","enrollment":75},{"nctId":"NCT04660344","phase":"PHASE3","title":"A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-05-03","conditions":"Muscle-invasive Bladder Cancer","enrollment":761},{"nctId":"NCT07492771","phase":"PHASE1","title":"MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia","status":"NOT_YET_RECRUITING","sponsor":"MicrobiotiX Co., Ltd","startDate":"2026-03","conditions":"Pneumonia - Bacterial, Pseudomonas Aeruginosa Infection","enrollment":18},{"nctId":"NCT05826535","phase":"PHASE1, PHASE2","title":"Study of LYL314 in Aggressive Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Lyell Immunopharma, Inc.","startDate":"2023-05-09","conditions":"Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma","enrollment":270},{"nctId":"NCT05907239","phase":"NA","title":"Effects of Focal Extracorporeal Shock Wave Therapy in the Treatment of Temporomandibular Disorders of Muscular Origin","status":"RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2023-04-20","conditions":"Temporomandibular Joint Disorders, Extracorporeal Shockwave Therapy","enrollment":100},{"nctId":"NCT07493265","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy","status":"NOT_YET_RECRUITING","sponsor":"Eisai Inc.","startDate":"2026-03-23","conditions":"Narcolepsy","enrollment":64},{"nctId":"NCT07047144","phase":"PHASE2","title":"A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy","status":"RECRUITING","sponsor":"Scholar Rock, Inc.","startDate":"2025-09-15","conditions":"Spinal Muscular Atrophy, SMA, Spinal Muscular Atrophy Type 2","enrollment":52},{"nctId":"NCT06985498","phase":"PHASE2","title":"Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-06-01","conditions":"Acute Lymphobkastic Leukemia","enrollment":40},{"nctId":"NCT05583344","phase":"PHASE2","title":"Phase 2b Study of GSK4532990 in Adults With NASH","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2023-01-02","conditions":"Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease","enrollment":284},{"nctId":"NCT07491146","phase":"PHASE2","title":"Phase II Clinical Study of the Efficacy and Safety of HSK55718 in the Treatment of Abdominal Postoperative Pain","status":"NOT_YET_RECRUITING","sponsor":"Yingyong Zhou,MD,PhD","startDate":"2026-03-25","conditions":"Pain After Abdominal Surgery","enrollment":200},{"nctId":"NCT07123155","phase":"PHASE2","title":"Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)","status":"RECRUITING","sponsor":"Shionogi","startDate":"2025-10-30","conditions":"Pompe Disease","enrollment":45},{"nctId":"NCT06989437","phase":"PHASE2, PHASE3","title":"A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-10-03","conditions":"Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":982},{"nctId":"NCT03926299","phase":"NA","title":"Clinical Trial to Demonstrate That the Dual Laser Therapy is Effective for the Treatment of Vulvar Lichen Sclerosus","status":"COMPLETED","sponsor":"Prof. Dr. Volker Viereck","startDate":"2019-07-15","conditions":"Chronic Skin Disease, Vulvar Lichen Sclerosus","enrollment":66},{"nctId":"NCT07487909","phase":"PHASE1, PHASE2","title":"A Study of SJP-001 in Comparison With Fexofenadine and Naproxen Administered With Alcohol","status":"COMPLETED","sponsor":"Sen-Jam Pharmaceutical","startDate":"2025-09-30","conditions":"Healthy","enrollment":47},{"nctId":"NCT07486089","phase":"PHASE1, PHASE2","title":"Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)","status":"RECRUITING","sponsor":"Beijing Biotech","startDate":"2026-02-02","conditions":"Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer, Triple-Negative Breast Cancer (TNBC)","enrollment":60},{"nctId":"NCT05711394","phase":"PHASE3","title":"A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine","status":"RECRUITING","sponsor":"AbbVie","startDate":"2023-05-01","conditions":"Episodic Migraine","enrollment":450},{"nctId":"NCT05648968","phase":"PHASE3","title":"A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-12-30","conditions":"Warm Autoimmune Hemolytic Anemia (wAIHA)","enrollment":90},{"nctId":"NCT06750289","phase":"PHASE3","title":"Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-28","conditions":"Eosinophilic Asthma","enrollment":400},{"nctId":"NCT06463587","phase":"PHASE3","title":"Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)","status":"RECRUITING","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2024-06-25","conditions":"Generalized Myasthenia Gravis","enrollment":264},{"nctId":"NCT01577082","phase":"PHASE3","title":"Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2012-04-20","conditions":"Asthma","enrollment":542},{"nctId":"NCT05242484","phase":"PHASE2","title":"A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-09-19","conditions":"Colitis, Ulcerative","enrollment":577},{"nctId":"NCT06991257","phase":"PHASE2","title":"A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-06-19","conditions":"Heart Failure","enrollment":620},{"nctId":"NCT06421636","phase":"PHASE2","title":"A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-09-30","conditions":"Non-Transfusion Dependent Beta-Thalassemia (NTDT)","enrollment":95},{"nctId":"NCT07310901","phase":"PHASE1","title":"A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity","status":"RECRUITING","sponsor":"Corbus Pharmaceuticals Inc.","startDate":"2025-12-04","conditions":"Obese But Otherwise Healthy Participants","enrollment":252},{"nctId":"NCT06962839","phase":"PHASE2","title":"A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2025-06-05","conditions":"Macular Edema","enrollment":300},{"nctId":"NCT06137742","phase":"PHASE1, PHASE2","title":"A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2023-11-17","conditions":"Pulmonary Arterial Hypertension","enrollment":96},{"nctId":"NCT07476846","phase":"NA","title":"rhTPO Dose Escalation vs Eltrombopag Switch in ITP","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03","conditions":"Primary Immune Thrombocytopenia (ITP)","enrollment":112},{"nctId":"NCT07322887","phase":"PHASE2","title":"A Phase 2 Study to Assess the Effects of SUL-238 on High Energy Phosphates With ³¹P-MRS in Patients With Early, Untreated Parkinson's Disease","status":"NOT_YET_RECRUITING","sponsor":"GEN İlaç ve Sağlık Ürünleri A.Ş.","startDate":"2026-03-02","conditions":"Parkinson's Disease (PD)","enrollment":45},{"nctId":"NCT07404579","phase":"PHASE2","title":"Safety and Efficacy of HRS-9190 Compared to Rocuronium for Bolus Maintenance in Adults","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2026-03-06","conditions":"Neuromuscular Blockade","enrollment":90},{"nctId":"NCT03100149","phase":"PHASE2","title":"A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-06-27","conditions":"Parkinson's Disease","enrollment":316},{"nctId":"NCT07136415","phase":"PHASE4","title":"Comparing Digital Therapy, Trazodone, and Daridorexant for Menopause-Related Insomnia Symptoms","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-02-13","conditions":"Menopausal Women, Insomnia","enrollment":1000},{"nctId":"NCT07474467","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Autologous Adipose-derived Mesenchymal Stem Cells Therapy in Adults With Atrophic Scars","status":"NOT_YET_RECRUITING","sponsor":"CellinCells","startDate":"2026-08-01","conditions":"Atrophic Scar","enrollment":31},{"nctId":"NCT05811351","phase":"PHASE2","title":"A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2023-03-06","conditions":"Geographic Atrophy","enrollment":305},{"nctId":"NCT05115110","phase":"PHASE2, PHASE3","title":"A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-06-02","conditions":"Spinal Muscular Atrophy (SMA)","enrollment":259},{"nctId":"NCT05797610","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-08-08","conditions":"Primary IgA Nephropathy","enrollment":428},{"nctId":"NCT04468659","phase":"PHASE3","title":"AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Inc.","startDate":"2020-07-14","conditions":"Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease","enrollment":1400},{"nctId":"NCT07108283","phase":"PHASE2","title":"A Study of Zasocitinib in Adults With Nonsegmental Vitiligo","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-11-03","conditions":"Nonsegmental Vitiligo","enrollment":200},{"nctId":"NCT06813911","phase":"PHASE3","title":"Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-04-30","conditions":"Atherosclerotic Cardiovascular Disease (ASCVD)","enrollment":340},{"nctId":"NCT06529432","phase":"PHASE2","title":"A Study of Bupivacaine Liposome Injection in the Treatment of Pain After Thoracoscopic Surgery","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2026-03-03","conditions":"Local Analgesia Via Nerve Block","enrollment":96},{"nctId":"NCT00543374","phase":"PHASE3","title":"Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease","status":"COMPLETED","sponsor":"Mesoblast, Inc.","startDate":"2007-09-17","conditions":"Crohn's Disease","enrollment":98},{"nctId":"NCT05076175","phase":"PHASE2, PHASE3","title":"A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2022-05-30","conditions":"Colitis, Ulcerative","enrollment":120},{"nctId":"NCT00482092","phase":"PHASE3","title":"Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease","status":"COMPLETED","sponsor":"Mesoblast, Inc.","startDate":"2007-09-17","conditions":"Crohn's Disease","enrollment":330},{"nctId":"NCT04862221","phase":"PHASE2","title":"TReatment for ImmUne Mediated PathopHysiology","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2022-02-09","conditions":"Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy","enrollment":163},{"nctId":"NCT04396236","phase":"PHASE3","title":"A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2020-06-15","conditions":"Migraine","enrollment":851},{"nctId":"NCT05714969","phase":"PHASE2","title":"A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2023-03-21","conditions":"Thrombotic Thrombocytopenic Purpura (TTP)","enrollment":33},{"nctId":"NCT06534983","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2024-12-09","conditions":"Muscle-invasive Urothelial Carcinoma","enrollment":362},{"nctId":"NCT07327359","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia","status":"RECRUITING","sponsor":"Olix Pharmaceuticals, Inc.","startDate":"2025-12-04","conditions":"Androgenetic Alopecia (AGA)","enrollment":158},{"nctId":"NCT07284290","phase":"PHASE4","title":"Elucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia","status":"RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2025-12-08","conditions":"Dementia With Lewy Bodies, Parkinson Disease Dementia, Healthy Controls","enrollment":120},{"nctId":"NCT07443826","phase":"PHASE1, PHASE2","title":"CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy","status":"RECRUITING","sponsor":"Unlimited Biotechnology LLC","startDate":"2026-03-31","conditions":"Age-related Muscle Decline","enrollment":12},{"nctId":"NCT07326592","phase":"PHASE4","title":"Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD)","status":"NOT_YET_RECRUITING","sponsor":"CSL Behring","startDate":"2026-04-15","conditions":"Alpha1 Antitrypsin Deficiency, Alpha1-Proteinase Inhibitor Deficiency, Emphysema","enrollment":270},{"nctId":"NCT05846230","phase":"PHASE2","title":"Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2023-09-08","conditions":"Bronchiectasis","enrollment":268},{"nctId":"NCT06950294","phase":"EARLY_PHASE1","title":"iNO300 Therapy in Critically Ill Patients With Pneumonia","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-02-23","conditions":"Critical Illness, Pneumonia","enrollment":34},{"nctId":"NCT05125302","phase":"PHASE3","title":"Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)","status":"RECRUITING","sponsor":"AbbVie","startDate":"2022-01-13","conditions":"Migraine","enrollment":1059},{"nctId":"NCT07346144","phase":"PHASE1, PHASE2","title":"Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma","status":"NOT_YET_RECRUITING","sponsor":"Trogenix ltd","startDate":"2026-03","conditions":"Glioblastoma (GBM), High Grade Gliomas, Recurrent Glioblastoma","enrollment":68},{"nctId":"NCT07441317","phase":"PHASE3","title":"QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated Low Density Lipoprotein Cholesterol (LDL-C)","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-03","conditions":"Primary Hypercholesterolemia or Mixed Hyperlipidemia","enrollment":780},{"nctId":"NCT04873362","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-05-04","conditions":"Breast Cancer","enrollment":1188},{"nctId":"NCT04311671","phase":"PHASE3","title":"Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole","status":"COMPLETED","sponsor":"Medicines Development for Global Health","startDate":"2021-05-03","conditions":"Onchocerciasis","enrollment":12979},{"nctId":"NCT06047379","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","status":"RECRUITING","sponsor":"Neonc Technologies, Inc.","startDate":"2023-11-01","conditions":"Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult","enrollment":134},{"nctId":"NCT07443202","phase":"PHASE2","title":"Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE)","status":"ENROLLING_BY_INVITATION","sponsor":"Tarsus Pharmaceuticals, Inc.","startDate":"2025-12-05","conditions":"Ocular Rosacea","enrollment":155},{"nctId":"NCT06272487","phase":"PHASE2","title":"Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)","status":"COMPLETED","sponsor":"Alnylam Pharmaceuticals","startDate":"2024-02-29","conditions":"High Cardiovascular Risk, Hypertension","enrollment":375},{"nctId":"NCT04896008","phase":"PHASE3","title":"A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)","status":"COMPLETED","sponsor":"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA","startDate":"2021-12-01","conditions":"Pulmonary Arterial Hypertension","enrollment":173},{"nctId":"NCT04884360","phase":"PHASE3","title":"D9319C00001- 1L OC Mono Global RCT","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-05-31","conditions":"Ovarian Cancer","enrollment":366},{"nctId":"NCT05428033","phase":"PHASE3","title":"A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-07-11","conditions":"Attention Deficit/Hyperactivity Disorder","enrollment":574},{"nctId":"NCT06806033","phase":"PHASE2","title":"A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-03-05","conditions":"B-Cell Non-Hodgkins Lymphoma","enrollment":100},{"nctId":"NCT07434973","phase":"PHASE3","title":"Stratification and Treatment in Early Psychosis Study - PROMOTE","status":"NOT_YET_RECRUITING","sponsor":"University of Oxford","startDate":"2026-05-01","conditions":"Clinical High Risk for Psychosis (CHR), Clinical High Risk for Psychosis, Clinical High Risk for Developing Psychosis","enrollment":586},{"nctId":"NCT06351592","phase":"PHASE1, PHASE2","title":"First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-08-28","conditions":"Amyotrophic Lateral Sclerosis (ALS), Mutation in the Superoxide Dismutase-1 (SOD1) Gene","enrollment":42},{"nctId":"NCT07440225","phase":"PHASE2, PHASE3","title":"A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)","status":"NOT_YET_RECRUITING","sponsor":"EyeBiotech Ltd.","startDate":"2026-03-31","conditions":"Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization","enrollment":960},{"nctId":"NCT06942039","phase":"EARLY_PHASE1","title":"Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation","status":"RECRUITING","sponsor":"C17 Council","startDate":"2025-09-23","conditions":"CNS Embryonal Tumor, CNS, Medulloblastoma, Atypical Teratoid Rhabdoid Tumor","enrollment":15},{"nctId":"NCT05200936","phase":"PHASE2","title":"Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial","status":"COMPLETED","sponsor":"Definium Therapeutics US, Inc.","startDate":"2021-12-17","conditions":"ADHD, Attention Deficit Disorder","enrollment":53},{"nctId":"NCT07416682","phase":"EARLY_PHASE1","title":"CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell Neoplasms","status":"NOT_YET_RECRUITING","sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","startDate":"2026-01-31","conditions":"High-risk Plasma Cell Neoplasms","enrollment":20},{"nctId":"NCT05642962","phase":"PHASE1, PHASE2","title":"Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-11-30","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma","enrollment":17},{"nctId":"NCT07432958","phase":"PHASE2","title":"A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations","status":"NOT_YET_RECRUITING","sponsor":"Appello Pharmaceuticals, Inc.","startDate":"2026-03-09","conditions":"Parkinson Disease","enrollment":150},{"nctId":"NCT05125809","phase":"PHASE2, PHASE3","title":"Setrusumab vs Placebo for Osteogenesis Imperfecta","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ultragenyx Pharmaceutical Inc","startDate":"2022-02-21","conditions":"Osteogenesis Imperfecta","enrollment":183},{"nctId":"NCT07430917","phase":"PHASE2","title":"Safety and Efficacy of J147 in Acute Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"Abrexa Pharmaceuticals, Inc.","startDate":"2026-03-20","conditions":"Acute Ischemic Stroke","enrollment":196},{"nctId":"NCT07301320","phase":"PHASE2","title":"Epetraborole in Patients With Mycobacterium Abscessus Lung Disease","status":"NOT_YET_RECRUITING","sponsor":"Kevin Winthrop","startDate":"2026-03","conditions":"Mycobacterium Abscessus Infection","enrollment":84},{"nctId":"NCT04752774","phase":"PHASE1, PHASE2","title":"A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.","status":"RECRUITING","sponsor":"Ipsen","startDate":"2021-04-29","conditions":"Spasticity","enrollment":240},{"nctId":"NCT05653219","phase":"PHASE3","title":"A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-02-02","conditions":"Primary Immune Thrombocytopenia","enrollment":152},{"nctId":"NCT06005662","phase":"PHASE2","title":"Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2027-04","conditions":"Opioid Use Disorder","enrollment":""},{"nctId":"NCT07176390","phase":"PHASE2","title":"A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-10-08","conditions":"Arthritis, Rheumatoid","enrollment":182},{"nctId":"NCT04953884","phase":"PHASE3","title":"Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease (VWD) Patients <6 Years of Age","status":"COMPLETED","sponsor":"Octapharma","startDate":"2021-09-22","conditions":"Von Willebrand Disease","enrollment":12},{"nctId":"NCT04257929","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Harmony Biosciences Management, Inc.","startDate":"2020-12-09","conditions":"Prader-Willi Syndrome","enrollment":65},{"nctId":"NCT04221945","phase":"PHASE3","title":"Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-05-12","conditions":"Uterine Cervical Neoplasms","enrollment":1060},{"nctId":"NCT06515002","phase":"PHASE1, PHASE2","title":"A Study to Test How Well BI 3720931 is Tolerated and Whether it Improves Lung Function in People With Cystic Fibrosis (Lenticlair™ 1)","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2024-11-04","conditions":"Cystic Fibrosis","enrollment":5},{"nctId":"NCT05386550","phase":"PHASE3","title":"Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)","status":"TERMINATED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2022-10-06","conditions":"Head and Neck Cancer","enrollment":166},{"nctId":"NCT06178055","phase":"PHASE2","title":"A Study of the Efficacy and Safety of KUS121 in Participants With Acute Non-Arteritic Central Retinal Artery Occlusion (CRAO)","status":"COMPLETED","sponsor":"Kyoto Drug Discovery and Development Co., Ltd.","startDate":"2024-04-16","conditions":"Central Retinal Artery Occlusion","enrollment":17},{"nctId":"NCT07347405","phase":"PHASE1","title":"Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.","status":"RECRUITING","sponsor":"Francisco A Moreno","startDate":"2026-03","conditions":"Obsessive-Compulsive Disorder","enrollment":30},{"nctId":"NCT06335303","phase":"PHASE2","title":"A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2024-09-05","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":322},{"nctId":"NCT07251595","phase":"PHASE2","title":"A Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients With Non-segmental Vitiligo","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-12-05","conditions":"Non-segmental Vitiligo","enrollment":176},{"nctId":"NCT07418996","phase":"PHASE2","title":"Live Double Combined Lactobacillus Capsule for Vaginal Use（IIa）","status":"COMPLETED","sponsor":"Guangdong Longchuangji Pharmaceutical Co., Ltd.","startDate":"2021-05-18","conditions":"Bacterial Vaginosis (BV)","enrollment":57},{"nctId":"NCT05225961","phase":"PHASE4","title":"ATILA Project: Aspirin Versus Tirofiban in Endovascular Treatment for Patients With Acute Ischemic Stroke Due to Tandem Lesion","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2022-05-01","conditions":"Acute Ischemic Stroke","enrollment":240},{"nctId":"NCT07101939","phase":"PHASE2","title":"A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)","status":"RECRUITING","sponsor":"Actimed Therapeutics Ltd","startDate":"2025-06-23","conditions":"Obesity, Muscle Loss","enrollment":120},{"nctId":"NCT07388680","phase":"PHASE2, PHASE3","title":"Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune Pneumonia","status":"NOT_YET_RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2026-02-28","conditions":"Radiation-induced Lung Injury, Immune-related Pneumonia","enrollment":298},{"nctId":"NCT07412574","phase":"EARLY_PHASE1","title":"Vitamin E Supplementation As Adjunctive Therapy To Lower Inflammation In COVID-19 Patients","status":"COMPLETED","sponsor":"Universidad Veracruzana","startDate":"2020-09-27","conditions":"COVID - 19","enrollment":56},{"nctId":"NCT04544436","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-11-26","conditions":"Multiple Sclerosis","enrollment":864},{"nctId":"NCT04619420","phase":"PHASE2","title":"A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-01-06","conditions":"Alzheimer Disease, Cognitive Dysfunction, Dementia","enrollment":523},{"nctId":"NCT06053242","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain","status":"RECRUITING","sponsor":"Creative Medical Technology Holdings Inc","startDate":"2024-05-21","conditions":"Chronic Low-back Pain, Degenerative Disc Disease","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":92,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"high dose dual therapy","genericName":"high dose dual therapy","companyName":"National Taiwan University Hospital","companyId":"national-taiwan-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}